Novartis Ag (NVS) Other Accumulated Expenses (2009 - 2026)

Novartis Ag (NVS) has 13 years of Other Accumulated Expenses data on file, last reported at -$100.0 million in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to -$100.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100.0 million (changed N/A YoY) and the FY2024 annual result came in at $14.1 billion, up 6.74% from the prior year.
• Other Accumulated Expenses fell to -$100.0 million in Q1 2026 per NVS's latest filing, from $15.8 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was $15.8 billion in Q2 2025, with the low at -$100.0 million in Q1 2026.
• Average Other Accumulated Expenses over 5 years is $8.2 billion, with a median of $13.2 billion recorded in 2023.
• Year-over-year, Other Accumulated Expenses surged 1474.88% in 2023 and retreated 10.14% in 2024.
• Novartis Ag's Other Accumulated Expenses stood at $836.0 million in 2022, then surged by 1474.88% to $13.2 billion in 2023, then increased by 6.74% to $14.1 billion in 2024, then advanced by 12.49% to $15.8 billion in 2025, then tumbled by 100.63% to -$100.0 million in 2026.
• Business Quant data shows NVS's Other Accumulated Expenses at -$100.0 million in Q1 2026, $15.8 billion in Q2 2025, and $14.1 billion in Q4 2024.